NCT02613221View on ClinicalTrials.gov

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

October 6, 2017

Study Completion Date

March 30, 2018

Conditions
Colorectal Cancer
Interventions
DRUG

Panitumumab + TAS-102

panitumumab + TAS-102 combination therapy

Trial Locations (32)

Unknown

Nagoya

Kashiwa

Matsuyama

Kitakyushu

Kurume

Hakodate

Kushiro

Sapporo

Amagasaki

Kobe

Tsukuba

Kasama

Hiragi

Sagamihara

Ōsaki

Matsumoto

Sasebo

Yamatotakada

Takatsuki

Shinden

Shizuoka

Nakatogari

Koto-ku

Minato-ku

Chiba

Fukui

Fukuoka

Kumamoto

Okayama

Okinawa

Osaka

Toyama

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY